Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models.
They published their findings recently in the Journal of Virology.
Researchers from UGA and Sanofi Pasteur, which has a research and development collaboration agreement with UGA, will present their data tomorrow, March 30, at the World Vaccine Congress US 2016 in Washington, D.C.
“One of the problems with current influenza vaccines is that we have to make predictions about which virus strains will be most prevalent every year and build our vaccines around those predictions,” said Ted Ross, director of UGA’s Center for Vaccines and Immunology and Georgia Research Alliance Eminent Scholar in Infectious Diseases in the College of Veterinary Medicine. “What we have developed is a vaccine that protects against multiple different strains of H1N1 virus at once, so we might be able to one day replace the current standard of care with this more broadly cross-protective vaccine.”
The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus was similar to those found in pigs, but the virus now circulates as a seasonal form of influenza.
Using a technique called Computationally Optimized Broadly Reactive Antigen, or COBRA, UGA researchers Donald Carter, Christopher Darby and Bradford Lefoley, along with Ross, created nine prototype synthetic compound vaccines constructed using genetic sequences from multiple influenza virus strains.
The COBRA vaccines were designed to recognize H1N1 viruses isolated within the last 100 years, but many of the experimental vaccines produced immunity against influenza strains not included in the design. This means that scientists may be able to produce a vaccine that not only protects against recognized seasonal and pandemic influenza strains, but also strains that have yet to be discovered.
Because this vaccine is generated from the genetic sequences of multiple flu viruses, it may protect against many strains over several years, Ross said. That would also allow for year-round manufacturing of the vaccine, since scientists would not have to halt production every year to identify the most prevalent strains.
This research is part of a broader effort to create a universal influenza vaccine, which would protect against all strains of the virus.
“We still have some work to do before we get a truly universal flu vaccine,” Ross said. “But the COBRA vaccine we’ve developed for H1N1 virus subtypes is a major step in the right direction.”
The Latest on: Flu vaccine
via Google News
The Latest on: Flu vaccine
- Avian Influenza, H5N8, Spreading Rapidly In Europe, What To Do About The Bird Fluon November 29, 2020 at 11:59 am
Multiple European countries, including Belgium, Denmark, France, Germany, Ireland, the Netherlands, Sweden, and the United Kingdom, have already reported outbreaks of highly pathogenic avian influenza ...
- Labor Law: Can employers require workers to take a flu - or COVID-19 - vaccine?on November 28, 2020 at 3:11 pm
Each year employers, especially in health care and those working with the elderly, require that employees receive the influenza vaccine, although there have always been legal constraints to mandating ...
- How South Korea responded to fears over the flu vaccineon November 28, 2020 at 6:24 am
South Korea had vastly expanded its flu vaccine program to cover millions more people, to prevent a one-two punch to its health system as the coronavirus spread globally. But as the injections got ...
- Flint-area drive through and curbside flu vaccine clinics offered at no coston November 27, 2020 at 12:12 pm
Hamilton Community Health Network is offering drive-through and curbside no-cost flu vaccine clinics starting Monday, Nov. 30. Flu viruses are most active in December, January and February, a Nov. 25, ...
- Seasonal Influenza Vaccine Market 2020 Market Segment, Drivers, Trends, Forecast to 2025on November 25, 2020 at 2:07 pm
Global Seasonal Influenza Vaccine Market Research Report 2020 Cover Covid-19 Impact The study on the ‘Seasonal ...
- New study explains important cause of fatal influenzaon November 25, 2020 at 6:16 am
It is largely unknown why influenza infections lead to an increased risk of bacterial pneumonia. Researchers at Karolinska Institutet have now described important findings leading to so-called ...
- 1 Lesson From The Influenza Pandemic 100 Years Ago That Still Applies Todayon November 25, 2020 at 5:12 am
Dr. Brown shared lessons from the 1918 influenza pandemic that are still relevant today. Corinne Cardina: I'd like to get a little bit more general now, I want to hear about influenza. You, of course, ...
- How South Korea’s Flu Vaccine Scare Offers Lessons for Other Nationson November 24, 2020 at 3:47 pm
Officials and scientists fought misinformation with data and clear communication — offering a game plan for the rollout of Covid-19 vaccines, experts say.
- Roche: FDA Approves Influenza Drug Xofluza For Post-exposure Prophylaxison November 23, 2020 at 10:48 pm
(RTTNews) - Swiss drug maker Roche Group (RHHBY) announced Tuesday that the U.S. Food and Drug Administration has approved a supplemental New Drug Application or sNDA for Xofluza (baloxavir marboxil) ...
- Flu (Influenza) Vaccine Market Analysis 2020, Growth Opportunities, Trends, Forecast to 2020on November 23, 2020 at 6:45 pm
Vaccine Market ” in Global to 2026 - Market Scope, Development, and Predictions offers the most up-to-date industry information on the actual market situation, and future outlook for vision frames and ...
via Bing News